Certara (700) Stock Forecast & Price Target

5 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

700 Analyst Ratings

Hold

1 Buy

7 Hold

0 Sell

Based on 8 analysts giving stock ratings to

Certara

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

700 Stock 12 Month Forecast

Average Price Target

€7.43

▲(6.91% Upside)

Based on 8 Wall Street analysts offering 12 month price targets for Certara in the last 3 months. The average price target is €7.43 with a high forecast of €8.83 and a low forecast of €6.18. The average price target represents a 6.91% change from the last price of €6.95.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3":"€3","12":"€12","5.25":"€5.25","7.5":"€7.5","9.75":"€9.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":8.8278005,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€8.83</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7.430065420833333,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€7.43</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6.17946035,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€6.18</span>\n  </div></div>","useHTML":true}}],"tickPositions":[3,5.25,7.5,9.75,12],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.952,8.019369269230769,8.086738538461539,8.154107807692307,8.221477076923078,8.288846346153846,8.356215615384615,8.423584884615385,8.490954153846154,8.558323423076923,8.625692692307693,8.693061961538461,8.760431230769232,{"y":8.8278005,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.952,7.911851186217949,7.871702372435897,7.831553558653846,7.7914047448717945,7.7512559310897435,7.711107117307693,7.670958303525641,7.63080948974359,7.590660675961539,7.550511862179487,7.510363048397436,7.470214234615384,{"y":7.430065420833333,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.952,7.815650796153846,7.679301592307692,7.542952388461538,7.406603184615385,7.270253980769231,7.133904776923077,6.997555573076923,6.86120636923077,6.724857165384615,6.588507961538462,6.452158757692308,6.3158095538461545,{"y":6.17946035,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":11.41,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.04,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.79,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.546,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.264,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.154,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.724,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.084,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.07,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.034,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.764,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.986,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.952,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€8.83

Average Price Target€7.43

Lowest Price Target€6.18

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Kevin Caliendo

UBS

€8.83

Hold

27.02%

Upside

Downgraded

09/30/26

Certara resumed with a Neutral at UBSCertara resumed with a Neutral at UBS

Craig Hettenbach

Morgan Stanley

€7.95

Hold

14.32%

Upside

Reiterated

09/17/26

Certara: Hold Rating Reiterated as Transition Risks Offset Long-Term Biosimulation and AI Upside; $9 Price Target Maintained

Luke Sergott

Barclays

€5.74→€6.62

Hold

-4.74%

Downside

Reiterated

08/05/26

Barclays Sticks to Its Hold Rating for Certara (CERT)

Joseph Vruwink

Robert W. Baird

€5.3→€6.18

Hold

-11.09%

Downside

Reiterated

08/05/26

Certara price target raised to $7 from $6 at BairdCertara price target raised to $7 from $6 at Baird

Jared Haase

William Blair

―

Hold

―

Reiterated

08/05/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Pediatrix Medical Group (NYSE: MD), Certara (NASDAQ: CERT) and Gilead Sciences (NASDAQ: GILD)

Brendan Smith

TD Cowen

€7.95

Buy

14.32%

Upside

Reiterated

08/04/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Arvinas Holding Company (NASDAQ: ARVN), Certara (NASDAQ: CERT) and Helus Pharma (NASDAQ: HELP)

Matt Hewitt

Craig-Hallum

―

Hold

―

Reiterated

08/04/26

Analysts Offer Insights on Healthcare Companies: Design Therapeutics (NASDAQ: DSGN), Certara (NASDAQ: CERT) and GeneDx Holdings (NASDAQ: WGS)

Sean Dodge

BMO Capital

€5.3→€7.06

Hold

1.61%

Upside

Reiterated

08/04/26

BMO Capital Sticks to Its Hold Rating for Certara (CERT)

Michael Cherny

Leerink Partners

€7.06

Buy

1.61%

Upside

Reiterated

06/16/26

Certara Rated Buy as Peer Deal Underscores Discounted Valuation and Supports Long-Term Growth Upside

Jeffrey Garro

Stephens

€8.83→€7.95

Buy

14.32%

Upside

Reiterated

05/12/26

Certara price target lowered to $9 from $10 at StephensCertara price target lowered to $9 from $10 at Stephens

Scott Schoenhaus

KeyBanc

€8.83→€7.06

Buy

1.61%

Upside

Assigned

04/13/26

Analysts Offer Insights on Healthcare Companies: IDEAYA Biosciences (NASDAQ: IDYA) and Certara (NASDAQ: CERT)

Dan Leonard

RBC Capital

€13.24→€8.83

Buy

27.02%

Upside

Assigned

03/09/26

Certara: Capitalizing on Growing Biosimulation Adoption Despite Near-Term Software Headwinds

Jamie Clark

Rothschild & Co Redburn

€8.83

Buy

27.02%

Upside

Initiated

11/21/25

Certara initiated with a Buy at Rothschild & Co RedburnCertara initiated with a Buy at Rothschild & Co Redburn

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Kevin Caliendo

UBS

€8.83

Hold

27.02%

Upside

Downgraded

09/30/26

Certara resumed with a Neutral at UBSCertara resumed with a Neutral at UBS

Craig Hettenbach

Morgan Stanley

€7.95

Hold

14.32%

Upside

Reiterated

09/17/26

Certara: Hold Rating Reiterated as Transition Risks Offset Long-Term Biosimulation and AI Upside; $9 Price Target Maintained

Luke Sergott

Barclays

€5.74→€6.62

Hold

-4.74%

Downside

Reiterated

08/05/26

Barclays Sticks to Its Hold Rating for Certara (CERT)

Joseph Vruwink

Robert W. Baird

€5.3→€6.18

Hold

-11.09%

Downside

Reiterated

08/05/26

Certara price target raised to $7 from $6 at BairdCertara price target raised to $7 from $6 at Baird

Jared Haase

William Blair

―

Hold

―

Reiterated

08/05/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Pediatrix Medical Group (NYSE: MD), Certara (NASDAQ: CERT) and Gilead Sciences (NASDAQ: GILD)

Brendan Smith

TD Cowen

€7.95

Buy

14.32%

Upside

Reiterated

08/04/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Arvinas Holding Company (NASDAQ: ARVN), Certara (NASDAQ: CERT) and Helus Pharma (NASDAQ: HELP)

Matt Hewitt

Craig-Hallum

―

Hold

―

Reiterated

08/04/26

Analysts Offer Insights on Healthcare Companies: Design Therapeutics (NASDAQ: DSGN), Certara (NASDAQ: CERT) and GeneDx Holdings (NASDAQ: WGS)

Sean Dodge

BMO Capital

€5.3→€7.06

Hold

1.61%

Upside

Reiterated

08/04/26

BMO Capital Sticks to Its Hold Rating for Certara (CERT)

Michael Cherny

Leerink Partners

€7.06

Buy

1.61%

Upside

Reiterated

06/16/26

Certara Rated Buy as Peer Deal Underscores Discounted Valuation and Supports Long-Term Growth Upside

Jeffrey Garro

Stephens

€8.83→€7.95

Buy

14.32%

Upside

Reiterated

05/12/26

Certara price target lowered to $9 from $10 at StephensCertara price target lowered to $9 from $10 at Stephens

Scott Schoenhaus

KeyBanc

€8.83→€7.06

Buy

1.61%

Upside

Assigned

04/13/26

Analysts Offer Insights on Healthcare Companies: IDEAYA Biosciences (NASDAQ: IDYA) and Certara (NASDAQ: CERT)

Dan Leonard

RBC Capital

€13.24→€8.83

Buy

27.02%

Upside

Assigned

03/09/26

Certara: Capitalizing on Growing Biosimulation Adoption Despite Near-Term Software Headwinds

Jamie Clark

Rothschild & Co Redburn

€8.83

Buy

27.02%

Upside

Initiated

11/21/25

Certara initiated with a Buy at Rothschild & Co RedburnCertara initiated with a Buy at Rothschild & Co Redburn

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

OMCLOmnicell

KNSAKiniksa Pharmaceuticals

ACHVAchieve Life Sciences

AHCOAdaptHealth

ZVRAZevra Therapeutics

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Certara

3 Months

Dan LeonardRBC Capital

Success Rate

4/6 ratings generated profit

Average Return

-2.65%

Copying Dan Leonard's trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of -2.65% per trade.

1 Year

Brendan SmithTD Cowen

Success Rate

4/9 ratings generated profit

Average Return

-4.71%

Copying Brendan Smith's trades and holding each position for 1 Year would result in 44.44% of your transactions generating a profit, with an average return of -4.71% per trade.

2 Years

Brendan SmithTD Cowen

Success Rate

4/9 ratings generated profit

Average Return

+4.69%

Copying Brendan Smith's trades and holding each position for 2 Years would result in 44.44% of your transactions generating a profit, with an average return of +4.69% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

700 Analyst Recommendation Trends

Rating

Jun 26

Jul 26

Aug 26

Sep 26

Oct 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 700 has received 1 Buy Ratings, 8 Hold Ratings, and 0 Sell Ratings. 700 average Analyst price target in the past 3 months is 7.43.

Each month's total comprises the sum of three months' worth of ratings.

700 Financial Forecast

700 Earnings Forecast

Next quarter’s earnings estimate for 700 is €0.08 with a range of €0.07 to €0.09. The previous quarter’s EPS was €0.07. 700 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 700 has Performed in-line its overall industry.

700 Sales Forecast

Next quarter’s sales forecast for 700 is €81.69M with a range of €79.78M to €85.45M. The previous quarter’s sales results were €82.28M. 700 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 700 has Performed in-line its overall industry.

700 Stock Forecast FAQ

What is DE:700’s average 12-month price target, according to analysts?

Based on analyst ratings, Certara’s 12-month average price target is 7.43.

What is DE:700’s upside potential, based on the analysts’ average price target?

Certara has 6.91% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Certara a Buy, Sell or Hold?

Certara has a consensus rating of Hold, which is based on 1 buy ratings, 7 hold ratings and 0 sell ratings.

What is Certara’s share price target?

The average share price target for Certara is 7.43. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €8.83 ,and the lowest forecast is €6.18. The average share price target represents 6.91% Increase from the current price of €6.95.

What do analysts say about Certara?

Certara’s analyst rating consensus is a Hold. This is based on the ratings of 8 Wall Streets Analysts.

How can I buy shares of Certara?

To buy shares of DE:700, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Certara (700) Stock Forecast & Price Target

700 Analyst Ratings

700 Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Certara

700 Analyst Recommendation Trends

700 Financial Forecast

700 Earnings Forecast

700 Sales Forecast

700 Stock Forecast FAQ

Detailed List of Analyst Forecasts